Leerink Partnrs Comments on Zai Lab FY2026 Earnings

Zai Lab Limited (NASDAQ:ZLAB) – Analysts at Leerink Partnrs issued their FY2026 earnings per share (EPS) estimates for Zai Lab in a report released on Thursday, February 27th. Leerink Partnrs analyst J. Chang forecasts that the company will earn $0.18 per share for the year. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share.

A number of other equities research analysts have also recently commented on the company. Bank of America reiterated a “neutral” rating and set a $36.10 target price (up previously from $29.00) on shares of Zai Lab in a report on Monday. Cantor Fitzgerald raised shares of Zai Lab to a “strong-buy” rating in a research report on Wednesday, February 5th.

Zai Lab Price Performance

Shares of NASDAQ ZLAB opened at $34.00 on Monday. The firm’s 50-day moving average is $27.77 and its two-hundred day moving average is $26.06. Zai Lab has a 12-month low of $13.48 and a 12-month high of $36.60. The company has a market capitalization of $3.72 billion, a PE ratio of -12.27 and a beta of 1.02.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.19). The firm had revenue of $109.07 million during the quarter, compared to analyst estimates of $110.15 million. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%.

Insider Activity at Zai Lab

In related news, insider Frazor Titus Edmondson III sold 14,544 shares of the firm’s stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $32.98, for a total transaction of $479,661.12. Following the sale, the insider now directly owns 14,328 shares in the company, valued at approximately $472,537.44. This trade represents a 50.37 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Ying Du sold 50,000 shares of Zai Lab stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $32.44, for a total transaction of $1,622,000.00. Following the sale, the chief executive officer now owns 494,117 shares in the company, valued at $16,029,155.48. This represents a 9.19 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 122,127 shares of company stock worth $4,024,442. 13.88% of the stock is owned by company insiders.

Hedge Funds Weigh In On Zai Lab

Institutional investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in Zai Lab during the 4th quarter valued at approximately $29,000. Pictet Asset Management Holding SA bought a new stake in shares of Zai Lab in the 4th quarter worth about $31,000. Barclays PLC lifted its position in shares of Zai Lab by 337.6% during the fourth quarter. Barclays PLC now owns 3,702 shares of the company’s stock worth $97,000 after purchasing an additional 2,856 shares during the last quarter. US Bancorp DE lifted its holdings in Zai Lab by 1,671.9% during the 4th quarter. US Bancorp DE now owns 5,865 shares of the company’s stock worth $154,000 after buying an additional 5,534 shares during the last quarter. Finally, Jasper Ridge Partners L.P. acquired a new stake in shares of Zai Lab during the 4th quarter valued at approximately $210,000. Institutional investors and hedge funds own 41.65% of the company’s stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.